South and Central America Cancer Hormone Therapy Market (2021–2031)

Growth in Hormone-Dependent Cancer Cases

Hormone-responsive cancers, especially breast and prostate cancers, are rising steadily across South and Central America due to aging populations, urbanization, and lifestyle changes such as dietary shifts and reduced physical activity. Brazil, Argentina, and Mexico report significant burdens of breast cancer, while prostate cancer remains common in countries across the region. Late-stage presentations and limited awareness in rural and underserved areas drive continued demand for hormone-based therapies.

Healthcare infrastructure is concentrated in major urban centers such as São Paulo, Buenos Aires, and Mexico City, where patients have access to a range of endocrine therapies and specialized oncology care. Smaller cities and rural areas face shortages of trained oncologists and limited laboratory capacity for hormone receptor testing and PSA monitoring, leading to reliance on regional referral networks for comprehensive management.

National and regional initiatives are improving access and standardizing care. Awareness campaigns, subsidized hormone therapies, and public health programs in countries such as Brazil, Colombia, and Chile aim to support early detection and ensure patients receive guideline-based treatment. As more patients enter formal care pathways, the growing prevalence of hormone-responsive cancers continues to drive demand for hormone therapies across South and Central America.

The Shift Toward Combination-Based Treatments

Combination therapy is gaining momentum across South and Central America, with hormone therapies paired with targeted agents or chemotherapy to enhance treatment outcomes. In breast cancer, endocrine therapies are commonly combined with CDK4/6 or mTOR inhibitors in advanced disease management, while prostate cancer regimens integrate androgen deprivation therapy with newer androgen receptor-targeted agents. Adoption is supported by alignment with international clinical guidelines and local experience from regional oncology centers.

Leading hospitals in urban hubs are establishing multidisciplinary care models to guide combination therapy. Genomic and hormone receptor testing, advanced imaging, and tumor boards help tailor regimens to individual patient profiles, ensuring more precise and effective treatment strategies. Pilot programs and regional registries further support evidence generation and adoption of combination approaches.

Policy and reimbursement developments are enabling wider use of combination therapies. Several countries are including innovative hormone-targeted regimens in public health programs, improving accessibility, while patients increasingly favor therapies that extend survival and minimize side effects.

The "South and Central America Cancer Hormone Therapy Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:

• South and Central America Cancer Hormone Therapy market size and forecast at regional and country levels for all the key market segments covered under the scope
• South and Central America Cancer Hormone Therapy market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• South and Central America Cancer Hormone Therapy market analysis covering key market trends, regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the South and Central America Cancer Hormone Therapy market
• Detailed company profiles, including SWOT analysis

The geographical scope of the South and Central America Cancer Hormone Therapy market report is divided into: Brazil, Argentina, Chile, Colombia, Peru, and the Rest of South and Central America. Brazil held the largest share in 2024.

Brazil dominates the market due to its relatively advanced healthcare system and the presence of well-established oncology centers. Hormone therapies are integrated into standard cancer treatment protocols, particularly for hormone-responsive cancers such as breast and prostate cancers. Urban hospitals and cancer institutes play a pivotal role in ensuring patient access to these therapies, while multidisciplinary care teams enhance the effectiveness of treatment through personalized planning and follow-up.

Brazil’s pharmaceutical sector, which includes domestic manufacturers and multinational companies, supports the availability of a broad range of hormone therapies. Clinical research initiatives and participation in international trials strengthen the adoption of innovative treatments and combination therapy strategies. Challenges remain, including disparities in access between urban and rural regions and the high cost of advanced therapies. Nevertheless, government initiatives to expand oncology services, improve training for healthcare professionals, and increase awareness about hormone therapy are helping Brazil maintain its leadership position in the market, setting the standard for neighboring countries in the region.

• The report includes qualitative and quantitative data in the South and Central America cancer Hormone therapy market across drug class, cancer type, route of administration, sales channel, and geography.
• The report starts with the key takeaways (chapter 2), highlighting the key trends and outlook of the South and Central America Cancer Hormone Therapy market.
• Chapter 3 includes the research methodology of the study.
• Chapter 4 further includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the South and Central America Cancer Hormone Therapy market, including factors that are driving the market, prevailing deterrents, and potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the South and Central America Cancer Hormone Therapy market scenario, in terms of historical market revenues, and forecast till the year 2031.
• Chapters 7 to 11 cover South and Central America Cancer Hormone Therapy market segments by drug class, cancer type, route of administration, sales channel, and geography across Brazil, Argentina, Chile, Colombia, Peru, and the Rest of South and Central America. They cover the market revenue, forecast, and factors driving the market.
• Chapter 12 describes the competitive analysis along with the heat map analysis for the key players operating in the market.
• Chapter 13 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape.
• Chapter 14 provides detailed profiles of the major companies operating in the South and Central America Cancer Hormone Therapy market. Companies have been profiled on the basis of their key facts, business descriptions, products, financial overview, SWOT analysis, and key developments.
• Chapter 15, i.e., the appendix, is inclusive of a brief overview of the company, list of abbreviations, and disclaimer.

The South and Central America Cancer Hormone Therapy market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the South and Central America cancer hormone therapy market are:

• In March 2024, Shanghai Henlius Biotech announced that its trastuzumab biosimilar HANQUYOU was approved for marketing in Brazil for the treatment of HER2‑positive breast cancer and gastric cancer, marking another major regulatory milestone and commercial expansion in Latin America. This approval enhances access to an important biologic therapy that is commonly used alongside hormone therapy in appropriate breast cancer subtypes in the region.
• In May 2022, Eurofarma announced that it would bring multiple cancer biosimilars — including trastuzumab — to Latin America through production, marketing, and distribution agreements, expanding the oncology portfolio available in Brazil, Mexico, Argentina, and other countries. Though not exclusive to hormone therapy drugs, trastuzumab products are widely used in breast cancer care, complementing hormone‑based treatment strategies.